PRVB News and Press, Provention Bio Inc. From 08/09/20

Provention Bio, Inc. (PRVB) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 ET Company Participants Andrew Drechsler - CFO Ashleigh Palmer - Co-Founder, President, CEO & Director Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientif...

Provention Bio (NASDAQ: PRVB ) : Q2 GAAP EPS of -$0.45 misses by $0.18 . Cash, cash equivalents and marketable securities of $172.2M as of June 30, 2020. Shares +2.6% . Press Release More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, ...

OLDWICK, N.J. , Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2020 and provided a busin...

Data by YCharts Introduction Provention Bio ( PRVB ) is a US biotechnology company developing biologics that target immune-mediated diseases. PRVB's therapeutic initiatives target endocrine diseases, infectious diseases, and respiratory diseases. This report will serve as a thor...

OLDWICK, N.J. , July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursd...

Investing in clinical-stage biotech stocks is risky. While positive results from clinical trials can send shares flying, the probability of a newly developed drug successfully making its way through all phases of the clinical trial process and earning regulatory approval is low. Still, picking t...

OLDWICK, N.J. , June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") ...

OLDWICK, N.J. , June 29, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has been added to the broad-market Russell 3000® Index and the small-cap Rus...

OLDWICK, N.J. , June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of the previously announced public offering of 7,590,000 shares of common sto...

Provention Bio (NASDAQ: PRVB )  +1%   prices its public offering of 6.6M common shares at $14.50 per share for gross proceeds of $95.7M. More news on: Provention Bio, Inc., Healthcare stocks news, , Read more ...